Skip to main content
SpringerLink
Log in

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate

  • ORIGINAL ARTICLE
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The aim of our study was to examine compliance with a daily dose of 5 mg alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stopped the medication in spite of having no AEs. A logistic regression analysis of factors that might have affected long-term compliance included AEs, an understanding of the disease, the method of ingestion, visiting medical facilities, the shape of the tablet, the cost of the drug, and the explanation of the doctor or pharmacist. This analysis showed that noncompliance occurred mainly due to AEs, the inconvenience of visiting a medical facility, unusual methods of ingestion, and a poor understanding of the disease. According to the results of the questionnaire for QOL assessment, the patients who continued the medication for more than 1 year had improved scores for pain in both the ALN and RDN groups. Osteoporotic treatment needs long-term patient compliance. To improve compliance, it is very important that doctors and pharmacists ensure that patients understand the purpose of this therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. RD Chapurlat PD Delmas (2006) ArticleTitleDrug insight: bisphosphonates for postmenopausal osteoporosis Nat Clin Pract Endocrinol Met 2 211–219 Occurrence Handle10.1038/ncpendmet0121 Occurrence Handle1:CAS:528:DC%2BD28XksFSrtLY%3D

    Article  CAS  Google Scholar 

  2. K Kushida M Shiraki T Nakamura H Kishimoto H Morii K Yamamoto K Kaneda M Fukunaga T Inoue M Nakashima H Orimo (2004) ArticleTitleAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study J Bone Miner Metab 22 462–468 Occurrence Handle15316867 Occurrence Handle10.1007/s00774-004-0508-0 Occurrence Handle1:CAS:528:DC%2BD2cXmslCit7c%3D

    Article  PubMed  CAS  Google Scholar 

  3. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs SuffixJr J Dequeker M Favus (1995) ArticleTitleEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Eng J Med 333 1437–1443 Occurrence Handle10.1056/NEJM199511303332201 Occurrence Handle1:CAS:528:DyaK28XkslehtA%3D%3D

    Article  CAS  Google Scholar 

  4. DM Black SR Cummings DB Karpt JA Cauley DE Tompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud (1996) ArticleTitleRandomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535–1541 Occurrence Handle8950879 Occurrence Handle10.1016/S0140-6736(96)07088-2 Occurrence Handle1:CAS:528:DyaK2sXisFCktQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  5. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix (1998) ArticleTitleEffect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures JAMA 280 2077–2082 Occurrence Handle9875874 Occurrence Handle10.1001/jama.280.24.2077 Occurrence Handle1:CAS:528:DyaK1MXjsVWruw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  6. KE Ensrud DM Black L Palermo DC Bauer E Barrett-Connor SA Quandt DE Thompson DB Karpf (1997) ArticleTitleTreatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial Arch Intern Med 157 2617–2624 Occurrence Handle9531231 Occurrence Handle10.1001/archinte.157.22.2617 Occurrence Handle1:CAS:528:DyaK2sXotVCksrg%3D

    Article  PubMed  CAS  Google Scholar 

  7. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut Suffix3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller (1999) ArticleTitleEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis JAMA 282 1344–1352 Occurrence Handle10527181 Occurrence Handle10.1001/jama.282.14.1344 Occurrence Handle1:CAS:528:DyaK1MXmvFansr0%3D

    Article  PubMed  CAS  Google Scholar 

  8. JY Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Rounagnac R Eastell (2000) ArticleTitleRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83–91 Occurrence Handle10663363 Occurrence Handle10.1007/s001980050010 Occurrence Handle1:CAS:528:DC%2BD3cXhvFGgsr0%3D

    Article  PubMed  CAS  Google Scholar 

  9. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier YJ Reginster (2001) ArticleTitleEffect of risedronate on the risk of hip fracture in elderly woman N Eng J Med 344 333–340 Occurrence Handle10.1056/NEJM200102013440503 Occurrence Handle1:CAS:528:DC%2BD3MXht1Wlu7g%3D

    Article  CAS  Google Scholar 

  10. JMS Macedo CRB Macedo H Elkis IRD Oliveira (1998) ArticleTitleMeta-analysis about the efficacy of anti-resorptive drugs in postmenopausal osteoporosis J Clin Parm Ther 23 345–352 Occurrence Handle10.1046/j.1365-2710.1998.00168.x Occurrence Handle1:CAS:528:DyaK1MXktFKquw%3D%3D

    Article  CAS  Google Scholar 

  11. A Cranney G Guyatt L Griffith G Wells P Tugwell C Rosen (2002) ArticleTitleSummary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570–576 Occurrence Handle12202472 Occurrence Handle10.1210/er.2001-9002 Occurrence Handle1:CAS:528:DC%2BD38Xnt1Whs78%3D

    Article  PubMed  CAS  Google Scholar 

  12. SE Andrade AM Walker LK Gottlieb NK Hollenberg MA Testa GM Saperia R Platt (1995) ArticleTitleDiscontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in a primary care setting? N Eng J Med 332 1125–1131 Occurrence Handle10.1056/NEJM199504273321703 Occurrence Handle1:STN:280:DyaK2M3hsVKkug%3D%3D

    Article  CAS  Google Scholar 

  13. B McClung M McClung (2001) ArticleTitlePharmacologic therapy for the treatment and prevention of osteoporosis Nurs Clin North Am 36 433–440 Occurrence Handle11532658 Occurrence Handle1:STN:280:DC%2BD3MvptFSgsA%3D%3D

    PubMed  CAS  Google Scholar 

  14. I Tanaka K Hayakawa H Oshima (2003) ArticleTitleTolerance of alendronate in patients with osteoporosis (in Japanese) Osteoporosis Japan 11 252–255

    Google Scholar 

  15. B Hamilton K McCoy H Taggart (2003) ArticleTitleTolerability and compliance with risedronate in clinical practice Osteoporos Int 14 259–262 Occurrence Handle12730745 Occurrence Handle1:CAS:528:DC%2BD3sXlslOlsL0%3D

    PubMed  CAS  Google Scholar 

  16. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick (2003) ArticleTitleCompliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965–968 Occurrence Handle14504697 Occurrence Handle10.1007/s00198-003-1502-4 Occurrence Handle1:CAS:528:DC%2BD3sXpvVCms74%3D

    Article  PubMed  CAS  Google Scholar 

  17. JJ Caro KJ Ishak KF Huybrechts G Raggio N Chistel (2004) ArticleTitleThe impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003–1008 Occurrence Handle15167989 Occurrence Handle10.1007/s00198-004-1652-z

    Article  PubMed  Google Scholar 

  18. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman (2006) ArticleTitleAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 IssueID8 1009–1012 Occurrence Handle10.4065/81.8.1013

    Article  Google Scholar 

  19. DH Solomon J Avorn JN Katz JS Finkelstein M Arnold JM Polinski MA Brookhart (2005) ArticleTitleCompliance with osteoporosis medications Arch Intern Med 165 2414–2419 Occurrence Handle16287772 Occurrence Handle10.1001/archinte.165.20.2414

    Article  PubMed  Google Scholar 

  20. JA Cramer S Silverman (2006) ArticleTitlePersistence with bisphosphonate treatment for osteoporosis: finding the root of the problem Am J Med 119 S12–17 Occurrence Handle16563936 Occurrence Handle10.1016/j.amjmed.2005.12.018 Occurrence Handle1:CAS:528:DC%2BD28Xks1Cgs70%3D

    Article  PubMed  CAS  Google Scholar 

  21. P Sambrook (2006) ArticleTitleCompliance with treatment in osteoporosis patients Aust Fam Physician 35 IssueID3 135–137 Occurrence Handle16525527

    PubMed  Google Scholar 

  22. MP Ettinger R Gallagher PE MacCosbe (2006) ArticleTitleMedication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 IssueID5 522–528 Occurrence Handle17002926

    PubMed  Google Scholar 

  23. JC Lo AR Pressman MA Omar B Ettinger (2006) ArticleTitlePersistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922–928 Occurrence Handle16609824 Occurrence Handle10.1007/s00198-006-0085-2 Occurrence Handle1:CAS:528:DC%2BD28XkvVCnurY%3D

    Article  PubMed  CAS  Google Scholar 

  24. N Miyakoshi E Itoi M Kobayashi H Komada (2003) ArticleTitleImpact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis Osteoporos Int 14 1007–1012 Occurrence Handle14557854 Occurrence Handle10.1007/s00198-003-1510-4 Occurrence Handle1:STN:280:DC%2BD3srpsFahsg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  25. K Kushida M Fukunaga H Kishimoto M Shiraki A Itabashi T Inoue K Kaneda H Morii H Nawata K Yamamoto Y Ohashi H Orimo (2004) ArticleTitleA comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial J Bone Miner Metab 22 469–478 Occurrence Handle15316868 Occurrence Handle1:CAS:528:DC%2BD2cXmslCit7g%3D

    PubMed  CAS  Google Scholar 

  26. E Romagnoli V Carnevale I Nofroni E D'Erasmo F Paglia SD Geronimo J Pepe N Raejntoph M Maranghi S Minisola (2004) ArticleTitleQuality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures Osteoporos Int 15 975–980 Occurrence Handle15118812 Occurrence Handle10.1007/s00198-004-1633-2

    Article  PubMed  Google Scholar 

  27. K Yoh K Tanaka A Ishikawa T Ishibashi Y Uchino Y Sato M Tobinaga N Hasegawa S Kamae M Yoshizawa (2005) ArticleTitleHealth-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment J Bone Miner Metab 23 167–173 Occurrence Handle15750696 Occurrence Handle10.1007/s00774-004-0556-5 Occurrence Handle1:CAS:528:DC%2BD2MXhvF2ru7Y%3D

    Article  PubMed  CAS  Google Scholar 

  28. AN Tosteson CS Hammond (2002) ArticleTitleQuality-of-life assessment in osteoporosis: health-status and preference-based measures Pharmacoeconomics 20 289–303 Occurrence Handle11994039 Occurrence Handle10.2165/00019053-200220050-00001

    Article  PubMed  Google Scholar 

  29. H Takahashi C Iwaya K Iba I Gorai T Suzuki Y Hayashi S Hujinawa K Yamasaki N Endo (2001) ArticleTitleThe Japanese Osteoporosis QOL Questionnaire (JOQOL): 2000 edition (in Japanese) J Jpn Soc Bone Miner Res 18 83–100

    Google Scholar 

  30. H Ohbayashi H Yamase (2004) ArticleTitleEfficacy of alendronate (Bonalon) in improving the quality of life of elderly Japanese patients with primary osteoporosis Osteoporosis Jpn 12 369–376

    Google Scholar 

  31. K Yamaoka T Tanigawara T Nakagawa T Uno (1981) ArticleTitleA pharmacokinetic analysis program (MULTI) for microcomputer J Pharmacobio-dyn 4 879–885 Occurrence Handle7328489 Occurrence Handle1:CAS:528:DyaL38XksFyntg%3D%3D

    PubMed  CAS  Google Scholar 

  32. S Aki N Eskiyurt U Akarirmak F Tuzun M Eryavuz S Alper O Arpacioglu F Atalay V Kavuncu S Kokino O Kuru K Nas O Ozerbil G Savas OF Sendur D Soy G Akyuz (2003) ArticleTitleGastrointestinal side-effect profile due to the use of alendronate in the treatment of osteoporosis Yonsei Med J 44 961–967 Occurrence Handle14703602 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOjtLw%3D

    PubMed  CAS  Google Scholar 

  33. FL Lanza RH Hunt AB Thomson JM Provenza MA Blank (2000) ArticleTitleEndoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal woman Gastroenterology 119 631–638 Occurrence Handle10982755 Occurrence Handle10.1053/gast.2000.16517 Occurrence Handle1:CAS:528:DC%2BD3cXmslSku7Y%3D

    Article  PubMed  CAS  Google Scholar 

  34. E Segal A Tamir S Ish-Shalom (2003) ArticleTitleCompliance of osteoporotic patients with different treatment regimens Isr Med Assoc J 5 IssueID12 859–862 Occurrence Handle14689753

    PubMed  Google Scholar 

  35. JA Cramer MM Amonkar A Hebborn R Altman (2005) ArticleTitleCompliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 IssueID9 1453–1460 Occurrence Handle16197664 Occurrence Handle10.1185/030079905X61875 Occurrence Handle1:CAS:528:DC%2BD2MXhtFKqu7zP

    Article  PubMed  CAS  Google Scholar 

  36. BJ Gertz SD Holland WF Kline BK Matuszewski A Freeman H Quan KC Lasseter JC Mucklow AG Porras (1995) ArticleTitleStudies of the oral bioavailability of alendronate Clin Pharmacol Ther 58 288–298 Occurrence Handle7554702 Occurrence Handle10.1016/0009-9236(95)90245-7 Occurrence Handle1:CAS:528:DyaK2MXpsVSltL8%3D

    Article  PubMed  CAS  Google Scholar 

  37. DY Mitchell WH Barr RA Eusebio KA Stevens FP Duke DA Russell JD Nesbitt JH Powell GA Thompson (2001) ArticleTitleRisedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration Pharm Res 18 166–170 Occurrence Handle11405286 Occurrence Handle10.1023/A:1011024200280 Occurrence Handle1:CAS:528:DC%2BD3MXktFOrur8%3D

    Article  PubMed  CAS  Google Scholar 

  38. PP Major A Lipton J Berenson G Hortobagyi (2000) ArticleTitleOral bisphosphonates Cancer 88 6–14 Occurrence Handle10618600 Occurrence Handle10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D Occurrence Handle1:CAS:528:DC%2BD3cXmtV2huw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  39. PD Delmas E Confavreux P Garnero E Confavreux P Garnero G Genolet G Gibelin J Yates (2001) ArticleTitleCan alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women J Bone Miner Rest 16 IssueIDSuppl 1 S406

    Google Scholar 

  40. DY Mitchell MA Heise KA Pallone ME Clay JD Nesbitt DA Russell CM Melson (1999) ArticleTitleThe effect of dosing regimen on the pharmacokinetics of risedronate Br J Clin Pharmacol 48 536–542 Occurrence Handle10583024 Occurrence Handle10.1046/j.1365-2125.1999.00035.x Occurrence Handle1:CAS:528:DyaK1MXmvFaksr4%3D

    Article  PubMed  CAS  Google Scholar 

  41. M Kamatari N Kataoka Y Watanabe M Tsuri Y Fukuda S Koto (2006) ArticleTitlePreference survey among osteoporotic patients with bisphosphonate treatment: once-daily and once-weekly dosing (in Japanese) Osteoporosis Jpn 14 IssueID4 765–768

    Google Scholar 

  42. JA Simon EM Lewiecki ME Smith RA Petruschke L Wang JJ Palmisano (2002) ArticleTitlePatient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study Clin Ther 24 IssueID11 1871–1886 Occurrence Handle12501880 Occurrence Handle10.1016/S0149-2918(02)80085-6 Occurrence Handle1:CAS:528:DC%2BD38Xpsleku7w%3D

    Article  PubMed  CAS  Google Scholar 

  43. D Kendler AWC Kung GE Fuleihan JGG Gonzalez KA Gaines N Verbruggen ME Melton (2004) ArticleTitlePatients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 243–251 Occurrence Handle15207890 Occurrence Handle10.1016/j.maturitas.2003.12.012 Occurrence Handle1:CAS:528:DC%2BD2cXltVCiu7o%3D

    Article  PubMed  CAS  Google Scholar 

  44. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings (1999) ArticleTitleMultiple outcomes of raloxifene evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637–645 Occurrence Handle10517716 Occurrence Handle10.1001/jama.282.7.637 Occurrence Handle1:CAS:528:DyaK1MXlvVKqurg%3D

    Article  PubMed  CAS  Google Scholar 

  45. EG Lufkin M Wong C Deal (2001) ArticleTitleThe role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis Rheum Dis Clin N Am 27 163–185 Occurrence Handle10.1016/S0889-857X(05)70192-7 Occurrence Handle1:STN:280:DC%2BD3MzpsVCmtg%3D%3D

    Article  CAS  Google Scholar 

  46. TW Downey SH Foltz SJ Boccuzzi MA Omar KH Kahler (2006) ArticleTitleAdherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting South Med J 99 IssueID6 570–575 Occurrence Handle16800411 Occurrence Handle10.1097/01.smj.0000221637.90495.66

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maruzen Pharmacy, 3-3-23-104 Nishimikuni, Yodogawa-ku, Osaka, 532-0006, Japan

    Masayuki Kamatari, Chie Urao, Yumiko Suzuki, Eri Akasaka, Kae Yanagimoto & Kazumi Sakota

  2. Koto Orthopedic, Internal Medicine Clinic, Osaka, Japan

    Shiro Koto & Nobuhiro Ozawa

  3. Kyoto Pharmaceutical University, 5 Nakauchi-cho, Yamashina-ku, Kyoto, Japan

    Masayuki Kamatari

Authors
  1. Masayuki Kamatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiro Koto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuhiro Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chie Urao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumiko Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eri Akasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kae Yanagimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazumi Sakota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Kamatari.

About this article

Cite this article

Kamatari, M., Koto, S., Ozawa, N. et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25, 302–309 (2007). https://doi.org/10.1007/s00774-007-0768-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-007-0768-6

Key words

Search

Navigation